The clinical trail of TRAIL

European Journal of Cancer

Volumn 42, Issue 14, 2006, Pages 2233-2240

  Duiker, E W ^a   Mom, C H ^a   de Jong, S ^a   Willemse, P H B ^a   Gietema, J A ^a   van der Zee, A G J ^a   de Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antibody; Apoptosis; RhTRAIL; Therapy; TRAIL

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CASPASE 8; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MAPATUMUMAB; MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; PACLITAXEL; PROTEIN BCL 2; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; AGONIST; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC ENCEPHALOMYELITIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CLINICAL TRIAL; DIMERIZATION; DNA DAMAGE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; HYPERAMYLASEMIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NONHODGKIN LYMPHOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RHEUMATOID ARTHRITIS; SEPSIS; SEQUENCE HOMOLOGY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL COMMUNICATION; DOWN-REGULATION; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33748100542     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.03.018     Document Type: Article

References (66)

1. Ogasawara J., Watanabefukunaga R., Adachi M., et al. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
2. Feinberg B., Kurzrock R., Talpaz M., et al. A phase-I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer-patients. J Clin Oncol 6 (1988) 1328-1334
3. Lejeune F.J., Kroon B.B., Di Filippo F., et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 10 (2001) 821-832 [ix]
4. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
5. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
6. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
7. Shankar S., and Srivastava R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7 (2004) 139-156
8. Truneh A., Sharma S., Silverman C., et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275 (2000) 23319-23325
9. Held J., and Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4 (2001) 243-252
10. Fulda S., and Debatin K.M. Modulation of TRAIL signaling for cancer therapy. Vitam Horm 67 (2004) 275-290
11. Wu G.S., Burns T.F., Zhan Y., Alnemri E.S., and El Deiry W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 59 (1999) 2770-2775
12. Smyth M.J., Takeda K., Hayakawa Y., et al. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 18 (2003) 1-6
13. Cretney E., Takeda K., Yagita H., et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168 (2002) 1356-1361
14. Spierings D.C., de Vries E.G., Vellenga E., et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 52 (2004) 821-831
15. Takeda K., Smyth M.J., Cretney E., et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195 (2002) 161-169
16. Cretney E., Shanker A., Yagita H., Smyth M.J., and Sayers T.J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 84 (2006) 87-98
17. Lub-de Hooge M.N., de Jong S., Vermot-Desroches C., et al. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock 22 (2004) 186-188
18. Lub-de Hooge M.N., de Vries E.G., de Jong S., and Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64 (2005) 854-858
19. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10 (2003) 66-75
20. Van Noesel M.M., van Bezouw S., Voute P.A., et al. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 38 (2003) 226-233
21. Hopkins-Donaldson S., Ziegler A., Kurtz S., et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10 (2003) 356-364
22. Horak P., Pils D., Haller G., et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3 (2005) 335-343
23. Van Geelen C.M., de Vries E.G., and de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7 (2004) 345-358
24. Stupack D.G., Teitz T., Potter M.D., et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439 (2006) 95-99
25. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 25 (2005) 31-58
26. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
27. Van Loo G., Saelens X., van Gurp M., et al. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 9 (2002) 1031-1042
28. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
29. Debatin K.M., and Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 23 (2004) 2950-2966
30. Kandasamy K., Srinivasula S.M., Alnemri E.S., et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 63 (2003) 1712-1721
31. Lindsten T., Ross A.J., King A., et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6 (2000) 1389-1399
32. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
33. LeBlanc H., Lawrence D., Varfolomeev E., et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8 (2002) 274-281
34. Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
35. Hay B.A., Wassarman D.A., and Rubin G.M. Drosophila homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. Cell 83 (1995) 1253-1262
36. Vaux D.L., and Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6 (2005) 287-297
37. Eckelman B.P., and Salvesen G.S. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 281 (2006) 3254-3260
38. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3 (2002) 401-410
39. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 139 (2003) 89-97
40. Wang X., Ju W., Renouard J., et al. 17-Allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res 66 (2006) 1089-1095
41. Franke T.F., Hornik C.P., Segev L., Shostak G.A., and Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 22 (2003) 8983-8998
42. Dan H.C., Sun M., Kaneko S., et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279 (2004) 5405-5412
43. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
44. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
45. Kelley S.K., Harris L.A., Xie D., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299 (2001) 31-38
46. Lawrence D., Shahrokh Z., Marsters S., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7 (2001) 383-385
47. Motoki K., Mori E., Matsumoto A., et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11 (2005) 3126-3135
48. Hirte H.W., Hotte S.J., Chen E.X., et al. HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase 1 trial. Clin Cancer Res 11 (2005) 9104s [abstr C22]
49. Mita M.T., Tolcher A.W., Patnaik A., et al. A phase I, pharmacokinetic (PK) study of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with solid tumors. Proc Am Assoc Cancer Res 46 (2005) 544
50. Younes A., Vose J., Zelenetz A.D., et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) (ETR1-HM01). Blood (ASH Annual Meeting Abstracts) 106 (2005) 489
51. Bonomi P., Greco F.A., Crawford J., et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer (NSCLC). Lung Cancer 49 Suppl. 2 (2005) S237 [abstr P460]
52. Kanzler S., Trarbach T., Heinemann V., et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). Eur J Cancer 3 Suppl. (2005) 177 [abstr 630]
53. Hariharan S., Gore L., Eckhardt S.G., et al. A phase 1 and pharmacological study of HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies. Clin Cancer Res 11 (2005) 9058s [abstr B109]
54. Mom C.H., Sleijfer S., Gietema J.A., et al. A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. Clin Cancer Res 11 (2005) 9117s [abstr C74]
55. Sarantopoulos J., Wakelee H., Mita M.T., et al. HGS-ETR2-ST02: a phase 1 clinical trial of HGS-ETR2, a fully human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors. Clin Cancer Res 11 (2005) 9104s [abstr C21]
56. Attard G., Plummer R.E., De Bono J.S., et al. Phase 1 and pharmakinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies. Clin Cancer Res 11 (2005) 9060s [abstr B114]
57. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
58. Singh T.R., Shankar S., and Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24 (2005) 4609-4623
59. Sayers T.J., and Murphy W.J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55 (2006) 76-84
60. Cummings J., Ward T.H., Ranson M., and Dive C. Apoptosis pathway-targeted drugs - from the bench to the clinic. Biochim Biophys Acta 1705 (2004) 53-66
61. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
62. Panner A., James C.D., Berger M.S., and Pieper R.O. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25 (2005) 8809-8823
63. Georgakis G.V., Li Y., Rassidakis G.Z., et al. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 12 (2006) 584-590
64. Ma Y., Lakshmikanthan V., Lewis R.W., and Kumar M.V. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol Cancer Ther 5 (2006) 170-178
65. Cuello M., Ettenberg S.A., Clark A.S., et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61 (2001) 4892-4900
66. Park S.Y., and Seol D.W. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295 (2002) 515-518